. 2026 Jan 1;158(1):45-59.

doi: 10.1002/ijc.70039. Epub 2025 Sep 5.

Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses

Amy Moore¹, Eleanor Kane², Lauren R Teras³, Mitchell J Machiela¹, Joshua Arias¹, Orestis A Panagiotou^{4

5}, Alain Monnereau^{6

7}, Nicole Wong Doo^{8

9}, Zhaoming Wang^{10

11}, Susan L Slager¹², Roel C H Vermeulen^{13

14}, Claire M Vajdic¹⁵, Karin E Smedby^{16

17}, John J Spinelli^{18

19}, Joseph Vijai²⁰, Graham G Giles^{9

21

22}, Brian K Link²³, Alan A Arslan^{24

25

26}, Alexandra Nieters²⁷, Paige M Bracci²⁸, Nicola J Camp²⁹, Gilles Salles¹⁹, Wendy Cozen³⁰, Henrik Hjalgrim^{31

32

33

34}, Immaculata De Vivo^{35

36}, Hans-Olov Adami^{36

37

38}, Demetrius Albanes¹, Nikolaus Becker³⁹, Yolanda Benavente^{40

41}, Simonetta Bisanzi⁴², Paolo Boffetta^{43

44}, Paul Brennan⁴⁵, Angela R Brooks-Wilson^{46

47}, Federico Canzian⁴⁸, Jacqueline Clavel^{6

49}, Lucia Conde⁵⁰, David G Cox⁵¹, Karen Curtin²⁹, Lenka Foretova⁵², Hervé Ghesquières^{53

54}, Bengt Glimelius⁵⁵, Thomas M Habermann⁵⁶, Jonathan N Hofmann¹, Qing Lan¹, Mark Liebow⁵⁶, Anne Lincoln¹⁹, Marc Maynadie⁵⁷, James McKay⁴⁵, Mads Melbye^{32

58

59

60}, Lucia Miligi⁶¹, Roger L Milne^{9

21

22}, Thierry J Molina⁶², Lindsay M Morton¹, Kari E North^{63

64}, Kenneth Offit¹⁹, Marina Padoan⁶⁵, Sara Piro⁶¹, Alpa V Patel¹⁹, Mark P Purdue¹, Vignesh Ravichandran¹⁹, Elio Riboli⁶⁶, Richard K Severson⁶⁷, Melissa C Southey^{9

22

68}, Anthony Staines⁶⁹, Lesley F Tinker⁷⁰, Ruth C Travis⁷¹, Sophia S Wang⁷², Elisabete Weiderpass⁴⁵, Stephanie Weinstein¹, Tongzhang Zheng⁷³, Stephen J Chanock¹, Nathaniel Rothman¹, Brenda M Birmann³⁵, James R Cerhan¹¹, Sonja I Berndt¹

Affiliations

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
² Department of Health Sciences, University of York, York, UK.
³ Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.
⁴ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
⁵ Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, Rhode Island, USA.
⁶ Unit of Mixed Research (UMR1153), Centre for Research in Epidemiology and Statistics (CRESS), INSERM, Université Paris-Cité, Paris, France.
⁷ Registre des hémopathies malignes de la Gironde, Institut Bergonié, Bordeaux Cedex, France.
⁸ Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.
⁹ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
¹⁰ Department of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹¹ Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
¹² Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
¹³ Department of Population Health Sciences, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
¹⁴ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁵ Surveillance and Evaluation Research Program, The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁶ Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
¹⁷ Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
¹⁸ Cancer Control Research, BC Cancer, Vancouver, British Columbia, Canada.
¹⁹ School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
²⁰ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²¹ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
²² Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
²³ Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
²⁴ Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York, USA.
²⁵ Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
²⁶ Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA.
²⁷ Center for Chronic Immunodeficiency, Institute for Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany.
²⁸ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
²⁹ Department of Internal Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.
³⁰ Division of Hematology-Oncology, Department of Medicine, University of California Irvine, Orange, California, USA.
³¹ Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
³² Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
³³ Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
³⁴ Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
³⁵ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
³⁶ Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
³⁷ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
³⁸ Institute of Health and Society, Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
³⁹ Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany.
⁴⁰ Cancer Epidemiology Research Programme, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain.
⁴¹ Unidad de Infecciones y Cáncer, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
⁴² Regional Laboratory for Cancer Prevention, Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Florence, Italy.
⁴³ Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York, USA.
⁴⁴ Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁴⁵ Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC), Lyon, France.
⁴⁶ Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
⁴⁷ Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.
⁴⁸ Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴⁹ National Registry of Childhood Cancers, APHP, CHU Paul Brousse, Villejuif and CHU de Nancy, France.
⁵⁰ Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, UK.
⁵¹ Cancer Research Center of Lyon, INSERM U1052, Centre Léon Bérard, Lyon, France.
⁵² Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
⁵³ Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.
⁵⁴ CIRI, Centre International de Recherche en Infectiologie, Team Lymphoma Immuno-Biology, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
⁵⁵ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
⁵⁶ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁵⁷ INSERM U1231, EA 4184, Registre des Hémopathies Malignes de Côte d'Or, University of Burgundy and Dijon University Hospital, Dijon, France.
⁵⁸ Medicine and Health Sciences Department, Jebsen Center for Genetic Epidemiology, NTNU, Trondheim, Norway.
⁵⁹ Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
⁶⁰ Department of Genetics, Stanford University Medical School, Stanford, California, USA.
⁶¹ Environmental and Occupational Epidemiology Unit, Cancer Prevention and Research Institute (ISPO), Florence, Italy.
⁶² Department of Pathology, APHP, Necker and Robert Debré, Université Paris Cité, Institut Imagine, INSERM U1163, Paris, France.
⁶³ Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁶⁴ Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁶⁵ Unit of Medical Statistics and Epidemiology, Department Translational Medicine, University of Eastern Piedmont "Amedeo Avogadro", Novara, Italy.
⁶⁶ Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK.
⁶⁷ Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, USA.
⁶⁸ Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
⁶⁹ School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland.
⁷⁰ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC, USA.
⁷¹ Cancer Epidemiology Unit, University of Oxford, Oxford, UK.
⁷² Division of Health Analytics, City of Hope Beckman Research Institute, Duarte, California, USA.
⁷³ Department of Epidemiology, Brown University, Providence, Rhode Island, USA.

PMID: 40910475
PMCID: PMC12588556
DOI: 10.1002/ijc.70039

Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses

Amy Moore et al. Int J Cancer. 2026.

. 2026 Jan 1;158(1):45-59.

doi: 10.1002/ijc.70039. Epub 2025 Sep 5.

Authors

Affiliations

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
² Department of Health Sciences, University of York, York, UK.
³ Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.
⁴ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
⁵ Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, Rhode Island, USA.
⁶ Unit of Mixed Research (UMR1153), Centre for Research in Epidemiology and Statistics (CRESS), INSERM, Université Paris-Cité, Paris, France.
⁷ Registre des hémopathies malignes de la Gironde, Institut Bergonié, Bordeaux Cedex, France.
⁸ Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.
⁹ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
¹⁰ Department of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹¹ Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
¹² Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
¹³ Department of Population Health Sciences, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
¹⁴ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁵ Surveillance and Evaluation Research Program, The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁶ Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
¹⁷ Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
¹⁸ Cancer Control Research, BC Cancer, Vancouver, British Columbia, Canada.
¹⁹ School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
²⁰ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²¹ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
²² Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
²³ Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
²⁴ Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York, USA.
²⁵ Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
²⁶ Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA.
²⁷ Center for Chronic Immunodeficiency, Institute for Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany.
²⁸ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
²⁹ Department of Internal Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.
³⁰ Division of Hematology-Oncology, Department of Medicine, University of California Irvine, Orange, California, USA.
³¹ Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
³² Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
³³ Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
³⁴ Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
³⁵ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
³⁶ Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
³⁷ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
³⁸ Institute of Health and Society, Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
³⁹ Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany.
⁴⁰ Cancer Epidemiology Research Programme, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain.
⁴¹ Unidad de Infecciones y Cáncer, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
⁴² Regional Laboratory for Cancer Prevention, Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Florence, Italy.
⁴³ Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York, USA.
⁴⁴ Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁴⁵ Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC), Lyon, France.
⁴⁶ Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
⁴⁷ Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.
⁴⁸ Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴⁹ National Registry of Childhood Cancers, APHP, CHU Paul Brousse, Villejuif and CHU de Nancy, France.
⁵⁰ Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, UK.
⁵¹ Cancer Research Center of Lyon, INSERM U1052, Centre Léon Bérard, Lyon, France.
⁵² Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
⁵³ Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.
⁵⁴ CIRI, Centre International de Recherche en Infectiologie, Team Lymphoma Immuno-Biology, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
⁵⁵ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
⁵⁶ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁵⁷ INSERM U1231, EA 4184, Registre des Hémopathies Malignes de Côte d'Or, University of Burgundy and Dijon University Hospital, Dijon, France.
⁵⁸ Medicine and Health Sciences Department, Jebsen Center for Genetic Epidemiology, NTNU, Trondheim, Norway.
⁵⁹ Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
⁶⁰ Department of Genetics, Stanford University Medical School, Stanford, California, USA.
⁶¹ Environmental and Occupational Epidemiology Unit, Cancer Prevention and Research Institute (ISPO), Florence, Italy.
⁶² Department of Pathology, APHP, Necker and Robert Debré, Université Paris Cité, Institut Imagine, INSERM U1163, Paris, France.
⁶³ Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁶⁴ Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁶⁵ Unit of Medical Statistics and Epidemiology, Department Translational Medicine, University of Eastern Piedmont "Amedeo Avogadro", Novara, Italy.
⁶⁶ Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK.
⁶⁷ Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, USA.
⁶⁸ Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
⁶⁹ School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland.
⁷⁰ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC, USA.
⁷¹ Cancer Epidemiology Unit, University of Oxford, Oxford, UK.
⁷² Division of Health Analytics, City of Hope Beckman Research Institute, Duarte, California, USA.
⁷³ Department of Epidemiology, Brown University, Providence, Rhode Island, USA.

PMID: 40910475
PMCID: PMC12588556
DOI: 10.1002/ijc.70039

Abstract

Obesity has been associated with non-Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome-wide association studies of European ancestry (N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05-1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR_{per SD} = 1.12, 95% CI: 1.02-1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.

© 2025 International Agency for Research on Cancer; licensed by UICC and The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

PubMed Disclaimer

Conflict of interest statement

G. Salles is on the advisory board for Abbvie, Beigene, BMS, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Merck, Novartis, and Nurix; consults for Abbvie, Atbtherapeutics, Beigene, BMS, Debiopharm, Genentech/Roche, Genmab, Innate Pharma, Incyte, Ipsen, Kite/Gilead, Modex, Molecular Partners, Nordic, Nanovector, Orna Therapeutics, and Treeline; receives research support from Abbvie, Genentech, Genmab, Janssen, Ipsen, and Nurix; and is a shareholder of Owkin. T.M. Habermann is on the data monitoring committee for Seagen and Eli Lilly and receives research program support from Roche/Genentech, BMS, and Genmab. The remaining authors have no conflicts of interest to declare.

Figures

**FIGURE 1**
Risk of four non‐Hodgkin lymphoma subtypes associated with genetically determined body mass index (BMI). Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for quartiles (Q1‐Q4) of the BMI polygenic score (PGS) and BMI PGS modeled as a linear term.

**FIGURE 2**
Risk of four non‐Hodgkin lymphoma subtypes associated with genetically determined waist‐to‐hip ratio adjusted for BMI (WHRadjBMI). Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for quartiles (Q1‐Q4) of the WHRadjBMI polygenic score (PGS) and WHRadjBMI PGS modeled as a linear term.

**FIGURE 3**
Risk of four non‐Hodgkin lymphoma subtypes associated with genetically determined waist‐to‐hip ratio (WHR). Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for quartiles (Q1‐Q4) of the WHR polygenic score (PGS) and WHR PGS modeled as a linear term.

**FIGURE 4**
Mendelian randomization analyses of body mass index (BMI) and the risk of four non‐Hodgkin lymphoma subtypes. Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for each subtype using the inverse variance weighted (IVW), weighted median, weighted mode, and MR Egger methods.

**FIGURE 5**
Mendelian randomization analyses of waist‐to‐hip ratio adjusted for body mass index (WHRadjBMI) and the risk of four non‐Hodgkin lymphoma subtypes. Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for each subtype using the inverse variance weighted (IVW), weighted median, weighted mode, and MR Egger methods.

**FIGURE 6**
Mendelian randomization analyses of waist‐to‐hip ratio (WHR) and the risk of four non‐Hodgkin lymphoma subtypes. Odds ratios (ORs) and 95% confidence intervals (CIs) are shown for each subtype using the inverse variance weighted (IVW), weighted median, weighted mode, and MR Egger methods.

See this image and copyright information in PMC

References

1. Chang ET, Hjalgrim H, Smedby KE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005;97(3):210‐218. doi: 10.1093/jnci/dji012 - DOI - PubMed
1. Britton JA, Khan AE, Rohrmann S, et al. Anthropometric characteristics and non‐Hodgkin's lymphoma and multiple myeloma risk in the European prospective investigation into cancer and nutrition (EPIC). Haematologica. 2008;93(11):1666‐1677. doi: 10.3324/haematol.13078 - DOI - PubMed
1. Willett EV, Morton LM, Hartge P, et al. Non‐Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph consortium. Int J Cancer. 2008;122(9):2062‐2070. doi: 10.1002/ijc.23344 - DOI - PMC - PubMed
1. Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective million women study. Br J Cancer. 2013;108(11):2390‐2398. doi: 10.1038/bjc.2013.159 - DOI - PMC - PubMed
1. Larsson SC, Wolk A. Obesity and risk of non‐Hodgkin's lymphoma: a meta‐analysis. Int J Cancer. 2007;121(7):1564‐1570. doi: 10.1002/ijc.22762 - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses

Affiliations

Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical